Lucid Genetics, Corp.

lucidgenes.com

Lucid Genetics is a clear way of understanding your body's genetic code and how it relates to your current and future health. Now, no matter where you are, you can meet with one of our boarded physicians to discuss a disease that has been in your family, an undiagnosed rare disease or your own history with a specific condition. From this live one on one meeting we can decide what genetic tests would be right for you.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Industrial Impact

MEMED RAISES $93M TO ACCELERATE COMMERCIALIZATION OF ITS HOST IMMUNE-RESPONSE PRODUCT PORTFOLIO

MeMed | January 10, 2022

news image

MeMed, a leader in host response technologies, announces a $93 million private financing round, bringing total funding in the Company to over $200 million, including support from the U.S. Department of Defense and EU Commission. Funds will be used to scale up manufacturing, accelerate commercialization and expand MeMed’s pioneering host immune response product portfolio. MeMed’s technology suite decodes the body’s immune response within minutes, providing p...

Read More

Industrial Impact

EMPATICA RECEIVES NEW FDA CLEARANCE FOR ITS HEALTH MONITORING PLATFORM AND ANNOUNCES SERIES B FINANCING

Empatica | November 23, 2022

news image

Empatica, a digital health and AI company developing medical-grade wearables and algorithms for health monitoring and diagnostics, today announced the clearance of its Empatica Health Monitoring Platform by the U.S. Food and Drug Administration. The Empatica Health Monitoring Platform is a full-stack remote health monitoring and data collection solution for research and healthcare professionals, built on data collected by Empatica's medical-grade, CE-certified EmbracePlus wear...

Read More

Industrial Impact

ADCENTRX AND AVANTGEN ENTER A NEW PARTNERSHIP WITH A THREE-YEAR, MULTI-TARGET COLLABORATION TO DISCOVER ANTIBODIES FOR NOVEL ANTIBODY-DRUG CONJUGATES

Adcentrx Therapeutics | February 15, 2022

news image

Adcentrx Therapeutics a biotechnology company focused on accelerating breakthroughs in antibody drug conjugate ("ADC") therapeutic development, and AvantGen, a leader in the use of yeast display technology for human antibody discovery and optimization, announced today a three-year, multi-target partnership for the discovery of antibodies to be developed into novel ADC therapeutic candidates. Under the terms of the collaboration, Adcentrx will specify targets against whic...

Read More

GENE THERAPY OFFERS HOPE FOR UNTREATABLE CTE BRAIN DISORDER

Genetic Literacy Project | January 14, 2020

news image

Researchers from Weill Cornell Medical College published a new study (“Anti-Phospho-Tau Gene Therapy for Chronic Traumatic Encephalopathy”) in Human Gene Therapy that shows the feasibility of using gene therapy to treat the progressive neurodegenerative disorder chronic traumatic encephalopathy (CTE). The study demonstrated the effectiveness of direct delivery of gene therapy into the brain of a mouse model of CTE....

Read More
news image

Industrial Impact

MEMED RAISES $93M TO ACCELERATE COMMERCIALIZATION OF ITS HOST IMMUNE-RESPONSE PRODUCT PORTFOLIO

MeMed | January 10, 2022

MeMed, a leader in host response technologies, announces a $93 million private financing round, bringing total funding in the Company to over $200 million, including support from the U.S. Department of Defense and EU Commission. Funds will be used to scale up manufacturing, accelerate commercialization and expand MeMed’s pioneering host immune response product portfolio. MeMed’s technology suite decodes the body’s immune response within minutes, providing p...

Read More
news image

Industrial Impact

EMPATICA RECEIVES NEW FDA CLEARANCE FOR ITS HEALTH MONITORING PLATFORM AND ANNOUNCES SERIES B FINANCING

Empatica | November 23, 2022

Empatica, a digital health and AI company developing medical-grade wearables and algorithms for health monitoring and diagnostics, today announced the clearance of its Empatica Health Monitoring Platform by the U.S. Food and Drug Administration. The Empatica Health Monitoring Platform is a full-stack remote health monitoring and data collection solution for research and healthcare professionals, built on data collected by Empatica's medical-grade, CE-certified EmbracePlus wear...

Read More
news image

Industrial Impact

ADCENTRX AND AVANTGEN ENTER A NEW PARTNERSHIP WITH A THREE-YEAR, MULTI-TARGET COLLABORATION TO DISCOVER ANTIBODIES FOR NOVEL ANTIBODY-DRUG CONJUGATES

Adcentrx Therapeutics | February 15, 2022

Adcentrx Therapeutics a biotechnology company focused on accelerating breakthroughs in antibody drug conjugate ("ADC") therapeutic development, and AvantGen, a leader in the use of yeast display technology for human antibody discovery and optimization, announced today a three-year, multi-target partnership for the discovery of antibodies to be developed into novel ADC therapeutic candidates. Under the terms of the collaboration, Adcentrx will specify targets against whic...

Read More
news image

GENE THERAPY OFFERS HOPE FOR UNTREATABLE CTE BRAIN DISORDER

Genetic Literacy Project | January 14, 2020

Researchers from Weill Cornell Medical College published a new study (“Anti-Phospho-Tau Gene Therapy for Chronic Traumatic Encephalopathy”) in Human Gene Therapy that shows the feasibility of using gene therapy to treat the progressive neurodegenerative disorder chronic traumatic encephalopathy (CTE). The study demonstrated the effectiveness of direct delivery of gene therapy into the brain of a mouse model of CTE....

Read More

Resources

resource image

Cell and Gene Therapy

VIA Thaw™ automated dry thawer

Video

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us